Long-term consequences and secondary prevention in patients who suffered acute coronary syndrome in real clinical practice based on the results of a 12-year follow-up
- 作者: Nikitina A.1, Egorova I.1, Vezikova N.1
-
隶属关系:
- Petrozavodsk State University
- 期: 卷 15, 编号 2 (2024)
- 页面: 124-134
- 栏目: Original study articles
- URL: https://journals.rcsi.science/2221-7185/article/view/263065
- DOI: https://doi.org/10.17816/CS626093
- ID: 263065
如何引用文章
全文:
详细
BACKGROUND: The analysis of the long-term consequences of acute coronary syndrome (ACS) revealed a high incidence of complications and their probable relationship with defects in secondary prevention, which allows us to determine the direction of elimination of such defects.
AIM: To assess the long-term consequences of ACS and the effectiveness of secondary prevention.
MATERIALS AND METHODS: The study included 255 patients who were sequentially hospitalized in the Regional Vascular Center of Petrozavodsk for ACS in 2009–2010. In the period from October 2021 to February 2022, electronic medical record data were retrospectively analyzed to assess the effects of ACS and the effectiveness of secondary prevention.
RESULTS: Data from 155 patients were analyzed, among whom men predominated (n=113, 72.9%). The mortality rate was high, with a significant prevalence of adverse effects of ACS. The 12-year mortality was 42.6% (66 people), and the average age of the deceased was 62.1±6.8 years. Chronic heart failure was diagnosed in 50 (32.3%) patients. Thirty-five of them had stage IIa (72.9% among 48 patients with a known stage), and 26 had functional class II (FC; 68.4% among 38 patients with a known FC). Stable angina pectoris was diagnosed in 41 patients (26.5%), 26 (66.7% among 39 patients with known FC) had symptoms of FC II, and 31 (20%) had recurrent ACS. Percutaneous intervention was performed in 65% of cases (n=20). Cardiac arrhythmias and conduction disorders were recorded in 41 (26.5%) patients: 15 of them (36.6%) were diagnosed with ventricular extrasystole of high grade (grade IV according to Ryan), and atrial fibrillation/flutter developed in 22 (14.2% of all observed) patients. Data indicate a lack of commitment to the principles of secondary prevention for both patients and doctors, except for quitting smoking. Six patients (3.9%) continued to smoke. Moreover, increased body weight persisted in 33 patients (21.3%). The prescription rate for necessary medications was low; acetylsalicylic acid was prescribed to 61 (39.4%) patients, blockers of the renin–angiotensin–aldosterone system to 74 (47.7%), beta-blockers to 74 (47.7%), and statins to 69 (44.5%), which does not allow achieving the target levels of therapy. The target blood pressure was achieved only in 68 patients (43.9%), heart rate in 23 (14.8%), and lipid spectrum in 2 (1.3%).
CONCLUSION: This study revealed the high incidence of adverse effects of ACS in the long-term period, which, apparently, is a consequence of low adherence to lifestyle modifications and drug correction of risk factors.
作者简介
Aglaya Nikitina
Petrozavodsk State University
编辑信件的主要联系方式.
Email: aglaia-nik@yandex.ru
ORCID iD: 0009-0005-2767-4915
SPIN 代码: 4035-8060
clinical resident
俄罗斯联邦, PetrozavodskInga Egorova
Petrozavodsk State University
Email: inga.skopets@gmail.com
ORCID iD: 0000-0002-5157-5547
SPIN 代码: 4981-2363
MD, Cand. Sci. (Med.), associate professor
俄罗斯联邦, PetrozavodskNatalia Vezikova
Petrozavodsk State University
Email: vezikov23@mail.ru
ORCID iD: 0000-0002-8901-3363
SPIN 代码: 3910-7360
MD, Dr. Sci. (Med.), professor, department head
俄罗斯联邦, Petrozavodsk参考
- Federal State Statistics Service [Internet]. [cited 2023 Dec 28]. Available from: https://rosstat.gov.ru/ (In Russ).
- Regional program «Fight against cardiovascular diseases in the Republic of Karelia for 2019-2024» [cited 2023 Dec 28]. Available from: https://gov.karelia.ru/upload/iblock/cc1/402r_P.pdf (In Russ).
- Lipid metabolism disorders [Internet]. Ministry of Health of the Russian Federation [cited 2023 Dec 28]. Available from: https://cr.minzdrav.gov.ru/schema/752_1 (In Russ).
- Acute coronary syndrome without ST segment elevation electrocardiogram [Internet]. Ministry of Health of the Russian Federation [cited 2023 Dec 28]. Available from: https://cr.minzdrav.gov.ru/recomend/154. (In Russ).
- Arterial hypertension in adults [Internet]. Ministry of Health of the Russian Federation [cited 2023 Dec 28]. Available from: https://cr.minzdrav.gov.ru/schema/62_2 (In Russ).
- Acute myocardial infarction with elevation of the ST segment of the electrocardiogram [Internet]. Ministry of Health of the Russian Federation [cited 2023 Dec 28]. Available from https://cr.minzdrav.gov.ru/schema/157_4 (In Russ).
- Boytsov SA, Alekyan BG, Shakhnovich RM, et al. What is changing in the treatment of acute coronary syndrome in the Russian Federation? Rational Pharmacotherapy in Cardiology. 2022;18(6):703–709. doi: 10.20996/1819-6446-2022-12-14
- Pereverzeva KG, Lukyanov MM, Andreenko EYu, et al. Outpatient register of patients who have suffered a myocardial infarction (REGATA): prospective follow-up data and outcomes. Kardiologiia. 2022;62(2):12–19. doi: 10.18087/cardio.2022.2.n1712
- Erdem G, Bakhai A, Taneja AK, et al. Rates and causes of death from non-ST elevation acute coronary syndromes: ten year follow-up of the PRAIS-UK registry. Int J Cardiol. 2013;168(1):490–494. doi: 10.1016/j.ijcard.2012.09.160
- Barbarash OL, Sedykh DYu, Gorbunova EV. Key factors determining the risk of recurrent myocardial infarction. Russian Heart Journal. 2017;16(1):26–31. doi: 10.18087/rhj.2017.1.2280
- Sodnomova LB, Zandanov AO, Shpak IA, et al. Gospital'nye i otdalennye iskhody u patsientov s ostrym koronarnym sindromom bez pod"ema segmenta ST. Sovremennye problemy nauki i obrazovaniya. 2019:(6). Available from: https://science-education.ru/ru/article/view?id=29370 (In Russ).
- Bessonov IS, Kuznetsov VA, Dyakova AO, et al. Percutaneous coronary interventions in patients with ST-elevation myocardial infarction: 10-years follow-up. Kardiologiia. 2020;60(6):69–75. doi: 10.18087/cardio.2020.6.n982
- Shulman VA, Shesternya PA, Golovenkin SE, et al. Prognostic value of atrial fibrillation with regard to early and late outcomes of myocardial infarction. Vestnik aritmologii. 2005;(39):5–9. Available from: http://www.vestar.ru/article.jsp?id=10347 (In Russ).
- Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2022, Issue 8 [cited 2023 Dec 28]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014936.pub2/full
- Yudi MB, Farouque O, Andrianopoulos N, et al. The prognostic significance of smoking cessation after acute coronary syndromes: an observational, multicentre study from the Melbourne interventional group registry. BMJ Open. 2017;7(10):e016874. doi: 10.1136/bmjopen-2017-016874
- Kontsevaya AV, Veretennikova AV, Rozanov VB, et al. Change in patients’ smoking behavior after a myocardial infarction according to a multicenter study. Profilakticheskaya meditsina. 2023;26(6):100–107. doi: 10.17116/profmed202326061100
- Pack QR, Rodriguez-Escudero JP, Thomas RJ, et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc. 2014;89(10):1368–1377. doi: 10.1016/j.mayocp.2014.04.033
- Williams MJA, Lee M, Alfadhel M, et al. Obesity and All Cause Mortality Following Acute Coronary Syndrome (ANZACS-QI 53). Heart Lung Circ. 2021;30(12):1854–1862. doi: 10.1016/j.hlc.2021.04.014
- Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330(7499):1059–1063. doi: 10.1136/bmj.330.7499.1059
- Everly MJ, Heaton PC, Cluxton RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004;38(2):286–293. doi: 10.1345/aph.1C472
- Kirichenko AA. Secondary prevention in stable angina. Consilium Medicum. 2019;21(10):27–33. doi: 10.26442/20751753.2019.10.190515
- Baigent C, Sudlow C, et al.; Antithromboci Trialists Collaborat. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. doi: 10.1136/bmj.324.7329.71
- Alekseeva IA, Sergienko IV. Atorvastatin in secondary prevention of cardiovascular diseases in the light of modern recommendations. Ateroskleroz i dislipidemii. 2017;(3):23–32. Available from: https://jad.noatero.ru/index.php/jad/article/download/209/207/208
- Athyros VG, Mikhailidis DP, et al.; GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004:20(5):627–637. doi: 10.1185/030079904125003421
- Boytsov SA, Piradov MA, Tanashyan MM, et al. Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(5):7–10. Available from: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2022/5/1199772982022051007
- Davidovich IM, Malay LN, Kutishenko NP. The analysis of long-term outcomes and adherent to treatment in patients after myocardial infarction: Khabarovsk register data. The Clinician. 2016–2017;(4–1):36–44. doi: 10.17650/1818-8338-2016-10-4-36-44
- Pogosova NV, Oganov RG, Boytsov SA, et al. Secondary prevention in patients with coronary artery disease in Russia and Europe: results from the Russian part of the EUROASPIRE V survey. Cardiovascular Therapy and Prevention. 2020;19(6):67–78. doi: 10.15829/1728-8800-2020-2739
- Ezhov MV, Sergienko IV, Ahmedzanov NM, et al. Dyslipidemia 2022 — how to reduce the risk and achieve the goal? Ateroskleroz i dislipidemii. 2022;3(48):59–68. doi: 10.34687/2219-8202.JAD.2022.03.0007
- Fomin IV, Polyakov DS, Badin YuV. EPOCH: arterial hypertension and coronary heart disease as the main causes of CHF. Effektivnaya farmakoterapiya: kardiologiya i angiologiya. 2011;(1):16–21. Available from: https://umedp.ru/articles/epokha_arterialnaya_gipertoniya_i_ishemicheskaya_bolezn_serdtsa_kak_osnovnye_prichiny_khsn.html?sphrase_id=124741 (In Russ).